Berdagang Vir Biotechnology VIR

VirBiotechnology carta live

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tunjukkan lebih lagi
Noah Lee 2025 Sep 25, 13:20

Xiaomi 17 Launch: Chip Strategy and Car Plans Unveiled

Liam James 2025 Sep 25, 12:20

Trump's Nobel Peace Prize Chances: Undermining International Order?

Ava Grace 2025 Sep 25, 09:20

White House Budget Office Directs Federal Agencies to Prepare for Mass Layoff Plans Amid Shutdown Fears

Liam James 2025 Sep 25, 09:20

Inflation Fears Grow: Is the US Economy Heading Towards Stagflation?

Sophia Claire 2025 Sep 25, 06:20

DoubleLine Capital Flags Concerns Over US Economic Data Quality, Turns to Alternative Sources

Liam James 2025 Sep 25, 04:20

Trump Shifts Ukraine Strategy: Pressure on Europe to Step Up

Sophia Claire 2025 Sep 25, 02:20

Trump Pledges to Arab Leaders He Won't Allow Israel to Annex West Bank

Ava Grace 2025 Sep 25, 01:20

Kremlin Dismisses Trump's Ukraine Stance Shift, Demands 'Real Information'

Maklumat

Sebaran nilai

0.05

Spread (%)

0.9766 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Jumaat

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Khamis

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

730700480

Saham Tertunggak

138916426

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-4.01

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tunjukkan lebih lagi
Trustpilot